Sujata Rao serves as Chief Medical Officer at CatalYm. She brings over two decades in early- and late-stage clinical development as well as medical affairs experience in oncology and immunology to the company. Working at renowned companies like Onyx, Bristol Myers Squibb, Eli Lilly/ARMO, and Insilico Medicine, Sujata built extensive expertise in FDA and global regulatory engagement, as well as IND and BLA preparation to advance novel therapies. As CMO of Insilico Medicine, she developed strategies and clinical oversight for the successful approval and out-licensing of oncology and non-oncology assets. Prior to that, Sujata was Associate Vice President of Global Clinical Development at Eli Lilly for immuno-oncology assets. As Immuno-Oncology Medical Lead and Oncology Scientific Advisor at Bristol-Myers Squibb for nivolumab, she led collaborative research efforts for rare malignancies and lung cancer.  Earlier in her career she was Sr. Medical Director at Onyx Pharmaceuticals, a subsidiary of Amgen, Inc. where she led efforts in liver, renal, and thyroid cancer for NEXAVAR®. Sujata completed her fellowship in medical oncology/hematology at Sloan Kettering Cancer Institute, New York.